You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Long-term Extension, Long-term Follow-up, AAV vector

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Enrolling by invitation
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • ADVM-022
  • Beverly Hills, California
  • +6 more
Nov 4, 2022

Male Hemophilia B Previously Treated With Etranacogene

Not yet recruiting
  • Hemophilia B
  • AAV5-hFIXco-Padua
  • (no location specified)
Jul 31, 2023

Long Term Follow-Up Gene Therapy Study for XLRP RPGR

Recruiting
  • X-Linked Retinitis Pigmentosa
  • AAV-RPGR
  • Boston, Massachusetts
  • +3 more
Dec 5, 2022

Parkinson Disease Trial in United States (AAV-GAD)

Enrolling by invitation
  • Parkinson Disease
  • AAV-GAD
  • West Bloomfield, Michigan
  • +4 more
Jun 7, 2023

Long-term Follow-up of RESTORE Study

Enrolling by invitation
  • Cancer
  • Long-term follow-up of cerena™
  • Long-term follow-up of attune™
  • San Francisco, California
    Blue Note Therapeutics
Dec 9, 2022

Study in Subjects Who Received vMCO-I Administered Via

Enrolling by invitation
  • Retinitis Pigmentosa
  • +2 more
  • Gene Therapy product:vMCO-I
  • Cuttack, Odisha, India
    JPM Rotary Club of Cuttack Eye Hospital and Research Institute
Jun 26, 2023

Severe Hemophilia A Subjects Who Received BMN 270 inPrior

Enrolling by invitation
  • Hemophilia A
    • London, United Kingdom
      Royal London Hospital, Barts and the London Hemophilia Center
    Mar 13, 2023

    AAV2hAQP1 for Radiation Induced Xerostomia

    Enrolling by invitation
    • Radiation-induced Xerostomia
      • Stanford, California
      • +3 more
      Dec 22, 2022

      Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in

      Not yet recruiting
      • Knee Osteoarthritis
        • (no location specified)
        Aug 28, 2023

        (LTFU) of Patients Treated With Genome-edited Autologous

        Not yet recruiting
        • Sickle Cell Disease
        • OTQ923
        • (no location specified)
        Nov 24, 2023

        Pulmonary Arterial Hypertension Trial in Indianapolis (AV-101)

        Recruiting
        • Pulmonary Arterial Hypertension
        • Indianapolis, Indiana
          Indiana University Health
        Dec 6, 2022

        Cancer Survivor, Prostate Carcinoma Trial in Duarte (Educational Intervention, Laboratory Biomarker Analysis, Long-term

        Active, not recruiting
        • Cancer Survivor
        • Prostate Carcinoma
        • Educational Intervention
        • +4 more
        • Duarte, California
          City of Hope Medical Center
        Jan 31, 2023

        Mobile Application for Follow-up of Cardiac Patients

        Recruiting
        • Follow-up
        • +2 more
        • Cardio2U follow-up
        • Edegem, Antwerp, Belgium
          University Hospital Antwerp
        Jul 10, 2023

        Patients Who Received Gene-Modified Cell Therapy

        Enrolling by invitation
        • Long-term Follow-up
        • Gene-Modified Cell Therapy
        • Philadelphia, Pennsylvania
          Abramson Cancer Center Clinical Research Unit, University of Pen
        Jul 21, 2022

        Long Term Follow-Up for RGX-111

        Enrolling by invitation
        • Mucopolysaccharidosis I
        • No Intervention
        • Orange, California
        • +2 more
        Oct 25, 2023

        Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

        Enrolling by invitation
        • Kidney Transplant Rejection
        • End Stage Renal Disease
        • Urine sample
        • +2 more
        • Leuven, Belgium
        • +5 more
        Aug 3, 2023

        Long Term Efficacy and Safety Trial (Imlifidase administered in the 20-HMedIdeS-19 (PAES) study, Best available treatment

        Not yet recruiting
        • Long Term Efficacy and Safety
        • Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
        • Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
        • (no location specified)
        Jun 30, 2023

        Achromatopsia Trial in Ann Arbor, London (either AAV - CNGB3 or AAV - CNGA3)

        Active, not recruiting
        • Achromatopsia
        • either AAV - CNGB3 or AAV - CNGA3
        • Ann Arbor, Michigan
        • +1 more
        Jan 13, 2022

        Patient With Anti-GABAbr Antibodies Associated-encephalitis.

        Completed
        • Autoimmune Encephalitis
        • Long-term outcome
        • Lyon, France
          Centre de référence des syndromes neurologiques paranéoplasiques
        Feb 14, 2023

        Long Term Follow up in Pediatric Supracondylar Humeral Fracture

        Not yet recruiting
        • Supracondylar Humerus Fracture
        • Elbow Fracture
          • (no location specified)
          Mar 20, 2023

          Study of Participants Previously Enrolled in the STARLIGHT Study

          Enrolling by invitation
          • Stargardt Disease
          • Gene Therapy Product-MCO-010
          • Miami, Florida
          • +1 more
          Sep 15, 2023

          Dietary Intervention to Stop Coronary Atherosclerosis in

          Enrolling by invitation
          • Coronary Artery Disease
          • +2 more
          • DISCO Intervention
          • Warszawa, Poland
            National Institute of Cardiology
          Sep 6, 2023

          A Long-Term Follow-Up Study of Participants Exposed to REACT

          Not yet recruiting
          • Diabetic Kidney Disease
          • Chronic Kidney Diseases
          • Renal Autologous Cell Therapy (REACT)
          • (no location specified)
          Jun 15, 2023

          Long-term Follow-up Study of COVID-19

          Recruiting
          • COVID-19
            • Wuhan, Hu Bei Province, China
            • +1 more
            Aug 8, 2023

            Fabry Disease Who Received Lentiviral Gene Therapy in Study

            Enrolling by invitation
            • Fabry Disease
            • Safety and Efficacy Assessments
            • Melbourne, Parkville VIC, Australia
            • +2 more
            Oct 5, 2022